Alberta Investment Management Corp Supernus Pharmaceuticals, Inc. Transaction History

Alberta Investment Management Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$34.93 - $42.03 $53,338 - $64,179	-1,527 Reduced 9.75%	14,142 $512,000
Q4 2022 Feb 14, 2023	BUY	$31.09 - $37.88 $487,149 - $593,541	15,669 New	15,669 $558,000
Q3 2021 Nov 15, 2021	SELL	$23.54 - $31.39 $741,510 - $988,785	-31,500 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$17.7 - $25.81 $228,330 - $332,949	-12,900 Reduced 29.05%	31,500 $793,000
Q3 2020 Oct 26, 2020	BUY	$20.2 - $25.05 $319,160 - $395,790	15,800 Added 55.24%	44,400 $925,000
Q2 2020 Aug 11, 2020	BUY	$17.09 - $24.89 $488,774 - $711,854	28,600 New	28,600 $679,000
Q2 2018 Aug 15, 2018	SELL	$44.1 - $59.85 $820,260 - $1.11 Million	-18,600 Closed	0 $0
Q1 2018 May 16, 2018	BUY	$37.15 - $46.9 $690,990 - $872,340	18,600 New	18,600 $852,000

283

60.6M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $2.11B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Alberta Investment Management Corp, based on Form 13F filings with the SEC.

Stay updated on Alberta Investment Management Corp with notifications on news.